LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Lyell Immunopharma Inc

Closed

0.42 5

Overview

Share price change

24h

Current

Min

0.4

Max

0.42

Key metrics

By Trading Economics

Income

140M

-52M

Sales

-4K

7K

EPS

-0.18

Profit margin

-745,642.857

Employees

300

EBITDA

58M

-119K

Recommendations

By TipRanks

Recommendations

Sell

12 Months Forecast

+150% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-1M

123M

Previous open

-4.58

Previous close

0.42

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Lyell Immunopharma Inc Chart

Past performance is not a reliable indicator of future results.

Related News

31 May 2025, 10:30 UTC

Top News

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 May 2025, 06:30 UTC

Earnings

5 Things We've Learned From Retail Earnings -- Barrons.com

31 May 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 May 2025, 23:51 UTC

Acquisitions, Mergers, Takeovers

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 May 2025, 21:30 UTC

Top News

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 May 2025, 21:15 UTC

Top News

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 May 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

30 May 2025, 20:44 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 May 2025, 20:24 UTC

Top News

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 May 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 May 2025, 19:44 UTC

Market Talk

Gold Breaks 4-Month Winning Streak -- Market Talk

30 May 2025, 19:38 UTC

Market Talk

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 May 2025, 19:29 UTC

Earnings
Acquisitions, Mergers, Takeovers

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 May 2025, 19:14 UTC

Market Talk

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 May 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 May 2025, 18:51 UTC

Market Talk

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 May 2025, 18:37 UTC

Market Talk
Earnings

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 May 2025, 18:04 UTC

Top News

S&P 500 Falls After More Trump-China Friction -- WSJ

30 May 2025, 17:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 May 2025, 17:47 UTC

Market Talk

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 May 2025, 17:40 UTC

Acquisitions, Mergers, Takeovers

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 May 2025, 17:38 UTC

Market Talk

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 May 2025, 17:31 UTC

Market Talk

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 May 2025, 17:14 UTC

Top News

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 May 2025, 16:31 UTC

Earnings

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 May 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

30 May 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

30 May 2025, 16:16 UTC

Top News

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 May 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 May 2025, 16:14 UTC

Top News

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Peer Comparison

Price change

Lyell Immunopharma Inc Forecast

Price Target

By TipRanks

150% upside

12 Months Forecast

Average 1 USD  150%

High 1 USD

Low 1 USD

Based on 3 Wall Street analysts offering 12 month price targets forLyell Immunopharma Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

3 ratings

0

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

0.4217 / 0.4691Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.